Physician profile
Maureen Richards
NPI 1134282122
$1,896.64
in general payments reported to CMS, 2019-2025
14 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $156 · 2021: $186 · 2022: $269 · 2023: $371 · 2024: $360 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.06 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $355.68 | 2019-2022 | |
| Abbvie INC. | $307.91 | 2023-2025 | |
| Alcon Vision LLC | $232.18 | 2022-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $220.66 | 2019-2023 | |
| Oyster Point Pharma, INC. | $202.10 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $164.11 | 2023-2025 | Miebo, Prolensa, Vyzulta |
| Sun Pharmaceutical Industries INC. | $116.57 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $83.93 | 2019-2021 | |
| Thea Pharma INC. | $64.97 | 2022-2024 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.07 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $35.53 | 2024 | Xdemvy |
| Harrow Eye, LLC | $30.56 | 2024 | Vevye |
| Astellas Pharma US INC | $22.28 | 2024 | Izervay |
| Biotissue Holdings INC. | $17.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.